Immune effector cell-associated acute stroke: A novel entity?
- PMID: 37852043
- DOI: 10.1016/j.ejca.2023.113352
Immune effector cell-associated acute stroke: A novel entity?
Conflict of interest statement
Declaration of Competing Interest R.H. reports honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche; and consultancy at Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte, Miltenyi. G.M. reports honoraria from BMC-cellgene and Gilead-Kite. M.M. and S.L. report no conflict of interest.
Comment on
-
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183. Neuro Oncol. 2021. PMID: 32750704 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical